Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivapalan, Lavanya, Murray, Joseph C, Canzoniero, Jenna VanLiere, Landon, Blair, Jackson, Jennifer, Scott, Susan, Lam, Vincent, Levy, Benjamin P., Sausen, Mark, Anagnostou, Valsamo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853269/
https://www.ncbi.nlm.nih.gov/pubmed/36657818
http://dx.doi.org/10.1136/jitc-2022-005924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853269/
https://www.ncbi.nlm.nih.gov/pubmed/36657818
http://dx.doi.org/10.1136/jitc-2022-005924

Ejemplares similares